Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) Equity Average (2016 - 2025)

OptimizeRx's Equity Average history spans 15 years, with the latest figure at $120.8 million for Q3 2025.

  • For Q3 2025, Equity Average rose 2.58% year-over-year to $120.8 million; the TTM value through Sep 2025 reached $120.8 million, up 2.58%, while the annual FY2024 figure was $121.8 million, 3.61% down from the prior year.
  • Equity Average for Q3 2025 was $120.8 million at OptimizeRx, up from $117.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $135.9 million in Q2 2022 and bottomed at $85.9 million in Q1 2021.
  • The 5-year median for Equity Average is $121.8 million (2024), against an average of $121.7 million.
  • The largest annual shift saw Equity Average skyrocketed 182.93% in 2021 before it fell 14.23% in 2023.
  • A 5-year view of Equity Average shows it stood at $129.1 million in 2021, then decreased by 0.97% to $127.8 million in 2022, then decreased by 5.09% to $121.3 million in 2023, then decreased by 4.61% to $115.7 million in 2024, then grew by 4.36% to $120.8 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Equity Average are $120.8 million (Q3 2025), $117.8 million (Q2 2025), and $116.6 million (Q1 2025).